ClinicalTrials.gg
RecruitingNCT07211412Updated Oct 22, 2026

Acute Cryotherapy on Musculoskeletal Function and Biomarkers

An interventional study of Cryotherapy and Eccentric exercise-induced muscle damage in Exercise Induced Muscle Damage and Cryotherapy, sponsored by University of Texas, El Paso. Recruiting at 1 site in United States. Open to participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University of Texas, El Paso · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 22, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 2,886 studies in Pain with a site in United States — 315 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.

Planned enrollment
1,333rd of 2,564
60 · median 66
Started
2025
with 128 others
No phase
1,244 of 2,886
183 open now
Primary completion
2027-12
later than 260 of 392 live
Registered
2,772nd of 2,886
by date

Among the 2,886 studies in Pain with a site in United States, this one is the 1,333rd largest by planned enrollment of the 2,564 interventional ones that give a count, is one of 129 that started in 2025, is one of 1,244 with no phase, reaches primary completion later than 260 of the 392 other live ones, and was the 2,772nd registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

315 of the 2,886 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

310 more — sign in →

All 315 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,886 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

In 2020, Dubois and Esculier proposed a paradigm shift in the acute management of musculoskeletal injuries, advocating for the transition from the traditional PRICE protocol- Protect, Rest, Ice, Compression, Elevation-to the more holistic PEACE \& LOVE framework. This updated model emphasizes Protection, Elevation, Avoiding anti-inflammatories, Compression, and Education, followed by Load, Optimism, Vascularization, and Exercise. Notably, the PEACE \& LOVE approach omits the use of ice, a decision that has sparked considerable debate. While the rationale centers on avoiding interference with the natural inflammatory and regenerative processes, this omission stands in contrast to a substantial body of animal research suggesting that cryotherapy can mitigate secondary tissue injury by reducing inflammation and metabolic activity. Despite its widespread clinical use, human studies have yet to provide conclusive evidence supporting or refuting the efficacy of cryotherapy in acute injury management, leaving clinicians to navigate between tradition, emerging evidence, and evolving philosophies of care. Even though it is important to consider natural inflammation for a better regenerative process, animal models have shown that the original injury can elicit oxidative stress, which will enhance cellular damage (secondary damage) and inflammation. Clinically, it is unknown if this secondary damage would increase functional impairment.

Therefore, this proposal will determine if cryotherapy can decrease secondary damage, after exercise-induced muscle damage, and if this decrease is associated to lower inflammation, oxidative stress and functional impairments.

Read the detailed description

This study is a randomized, double-blind, controlled clinical trial with 3 independent groups. One group (control-control or CON-CON) will not exercise and will not have any cryotherapy intervention, a second group (control or CON) will exercise but use a "room temperature" cold-pack, and the cryotherapy group (CRYO) will exercise and receive a cold cold-pack every day for 15-min.

Means of several markers (functional and in blood) will be analyzed by using a two-way analysis of variance (ANOVA, time x condition) where time is before, and 0, 24, 48, 72, 96, and 264 hours after exercise (6 visits) and conditions are CON-CON, CON, and CRYO.

VISIT ONE Before the informed consent process, potential participants will rest for 10 minutes, and their blood pressure will be taken to confirm eligibility. Once eligibility is confirmed, participants will go through the informed consent process. After the participants have signed the informed consent, the participants will be randomly allocated to one of the 3 groups. Then, a blood sample (two 10-ml tubes) from an antecubital vein of the dominant arm will be drawn. After the blood drawn, a set of functional tests ( i.e., arm girth, active range of motion (ROM), peak pressure threshold (PPT), and maximal voluntary isometric contraction (MVIC)) will be performed (the description of each test can be found below). Once the functional tests are performed, participants from the CON-CON group will be dismissed. Participants from the other 2 groups will perform a controlled exercise-induced muscle damage (EIMD) through eccentric exercise (protocol description below). Immediately after the EIMD protocol, participants in the CON group will receive 15-min of a room temperature cold-pack in room RSC 100. Participants in the CRYO group will receive 15-min of a cold cold-pack in room RSC 100. Treatment will be performed by RAs that were not involved in any testing session. After treatment, CON or CRYO, the same set of functional tests will be performed in room RSC 117.

VISIT TWO to FOUR (24, 48, and 72 hours after VISIT 1, respectively) Participants will get a blood draw (two 10-ml tubes) from an antecubital vein of the dominant arm. Then, participants in the CON group will receive 15-min of a room temperature cold-pack in room RSC 100. Participants in the CRYO group will receive 15-min of a cold cold-pack in room RSC 100. Treatment will be performed by RAs that were not involved in any testing session. Participants from the CON-CON group will not have any treatment. Finally, the set of functional tests will be performed.

VISIT FIVE (96 hours after VISIT 1) Participants will get only a blood draw (two 10-ml tubes) from an antecubital vein of the dominant arm. Then, participants in the CON group will receive 15-min of a room temperature cold-pack in room RSC 100. Participants in the CRYO group will receive 15-min of a cold cold-pack in room RSC 100. Treatment will be performed by RAs that were not involved in any testing session. Participants from the CON-CON group will not have any treatment.

VISIT SIX (264 hours after VISIT 1) Participants will get a blood draw (two 10-ml tubes) from an antecubital vein of the dominant arm. Then, the set of functional tests will be performed.

03

Conditions studied

  • Exercise Induced Muscle Damage
  • Cryotherapy

Browse trials for

Keywords

  • Exercise induced muscle damage
  • Cryotherapy
  • Cold-pack
  • Ice-pack
  • Eccentric exercise
  • Creatine kinase
  • c-reactive protein
  • interlukin-6
  • 8-isoprostane
  • Range of motion
  • Maximal Voluntary Isometric Contraction
  • Pain
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • apparently healthy
  • normotensive
  • non-smokers (all tobacco products including e-cigarettes)

Exclusion criteria

Exclusion Criteria:

  • Cardiovascular diseases (including hypertension)
  • pregnancy
  • any musculoskeletal injury 6 months prior the study
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • No intervention
    Control-control

    This arm will include no intervention and only functional assessments and blood draws for biomarkers.

  • Placebo comparator
    Control

    This arm will have eccentric exercise-induced muscle damage on day 0 and then 15-min of room temperature cold-pack immediately after and then for 4 more days every 24 hours.

    Other: Eccentric exercise-induced muscle damage

  • Active comparator
    Cryotherapy

    This arm will have eccentric exercise-induced muscle damage on day 0 and then 15-min of cold (-5°C) cold-pack immediately after and then for 4 more days every 24 hours.

    Other: Cryotherapy · Other: Eccentric exercise-induced muscle damage

Interventions

  • OtherCryotherapy

    A cold (-5°C) cold-pack for 15 minutes every 24 hours for 5 days

    Also known as: cold-pack, ice-pack

  • OtherEccentric exercise-induced muscle damage

    3 sets of 15 repetitions of eccentric contractions at 80% of 1RM. This is to induced a controlled muscle damage in 2 of the 3 arms.

    Also known as: doms

06

What researchers measure

Primary outcomes

  1. Maximal Voluntary Isometric Contraction (MVIC)

    Laid down on an isokinetic dynamometer system (Humac-Norm, Computer Sports Medicine, inc., Stoughton, MA), participants will be asked to flex their non-dominant arm (pull with their hand) against the dynamometer. They will perform 3 tries with 1 minute between tries and the peak value will be considered the MVIC.

    Time frame: From enrollment to the end of study at 12 days

  2. Peak Pressure Threshold (PPT)

    PPT is the application of an algometer, which measure pressure on a specific body point (see figure below), while asking the participant 2 questions: 1) tell me when the pressure becomes pain and 2) how much pain you felt from 0 to 100, where 0 is no pain and 100 is the larger pain you have ever experienced. PPT will be performed over the flexor muscles (biceps brachialis) of the non-dominant arm.

    Time frame: From enrollment to the end of study at 12 days.

  3. Creatine kinase

    Blood biomarker of muscle damage. Blood draws will be performed before and 0, 24, 48, 72, and 96 hours after EIMD.

    Time frame: From enrollment to the end of treatment at 5 days

  4. Interleukin-6

    Blood biomarker of inflammation. Blood draws will be performed before and 0, 24, 48, 72, and 96 hours after EIMD.

    Time frame: From enrollment to the end of treatment at 5 days

  5. 8-isoprostane

    Blood biomarker of oxidative stress. Blood draws will be performed before and 0, 24, 48, 72, and 96 hours after EIMD.

    Time frame: From enrollment to the end of treatment at 5 days

Secondary outcomes

  1. Arm girth

    With a flexible tape measure, the perimeter will be measured at the non-dominant arm, on the middle between the shoulder and the elbow.

    Time frame: From enrollment to the end of study at 12 days.

  2. Active Range of Motion (ROM)

    Participants will be asked to flex and extend the non-dominant elbow while wearing a wireless range of motion device (electronic goniometer, ActiveForce2, ActiveBody, San Diego, CA) (see picture below). The device will measure the active ROM.

    Time frame: From enrollment to the end of study at 12 days.

  3. C-reactive protein

    Blood biomarker of inflammation. Blood draws will be performed before and 0, 24, 48, 72, and 96 hours after EIMD.

    Time frame: From enrollment to the end of treatment at 5 days.

07

Study locations

1 of 1 sites recruiting
  • The University of Texas at El Paso, Rehabilitation Sciences Complex
    El Paso, Texas 79968, United States
    Recruiting
08

References and documents

Publications

  • Qu C, Wu Z, Xu M, Qin F, Dong Y, Wang Z, Zhao J. Cryotherapy Models and Timing-Sequence Recovery of Exercise-Induced Muscle Damage in Middle- and Long-Distance Runners. J Athl Train. 2020 Apr;55(4):329-335. doi: 10.4085/1062-6050-529-18. Epub 2020 Mar 11. PubMed 32160058 ↗
  • Pooley S, Spendiff O, Allen M, Moir HJ. Comparative efficacy of active recovery and cold water immersion as post-match recovery interventions in elite youth soccer. J Sports Sci. 2020 Jun-Jun;38(11-12):1423-1431. doi: 10.1080/02640414.2019.1660448. Epub 2019 Aug 28. PubMed 31456474 ↗
  • Rose C, Edwards KM, Siegler J, Graham K, Caillaud C. Whole-body Cryotherapy as a Recovery Technique after Exercise: A Review of the Literature. Int J Sports Med. 2017 Dec;38(14):1049-1060. doi: 10.1055/s-0043-114861. Epub 2017 Nov 21. PubMed 29161748 ↗
  • Kwiecien SY, McHugh MP, Hicks KM, Keane KM, Howatson G. Prolonging the duration of cooling does not enhance recovery following a marathon. Scand J Med Sci Sports. 2021 Jan;31(1):21-29. doi: 10.1111/sms.13822. Epub 2020 Sep 25. PubMed 32901996 ↗
  • Sasaki R, Sakamoto J, Kondo Y, Oga S, Takeshita I, Honda Y, Kataoka H, Origuchi T, Okita M. Effects of Cryotherapy Applied at Different Temperatures on Inflammatory Pain During the Acute Phase of Arthritis in Rats. Phys Ther. 2021 Feb 4;101(2):pzaa211. doi: 10.1093/ptj/pzaa211. PubMed 33351944 ↗
  • Merrick MA, Rankin JM, Andres FA, Hinman CL. A preliminary examination of cryotherapy and secondary injury in skeletal muscle. Med Sci Sports Exerc. 1999 Nov;31(11):1516-21. doi: 10.1097/00005768-199911000-00004. PubMed 10589851 ↗
  • Allan R, Malone J, Alexander J, Vorajee S, Ihsan M, Gregson W, Kwiecien S, Mawhinney C. Cold for centuries: a brief history of cryotherapies to improve health, injury and post-exercise recovery. Eur J Appl Physiol. 2022 May;122(5):1153-1162. doi: 10.1007/s00421-022-04915-5. Epub 2022 Feb 23. PubMed 35195747 ↗
  • Kwiecien SY, McHugh MP. The cold truth: the role of cryotherapy in the treatment of injury and recovery from exercise. Eur J Appl Physiol. 2021 Aug;121(8):2125-2142. doi: 10.1007/s00421-021-04683-8. Epub 2021 Apr 20. PubMed 33877402 ↗
  • Dubois B, Esculier JF. Soft-tissue injuries simply need PEACE and LOVE. Br J Sports Med. 2020 Jan;54(2):72-73. doi: 10.1136/bjsports-2019-101253. Epub 2019 Aug 3. No abstract available. PubMed 31377722 ↗

Individual participant data

Plan to share: No — I might share un-identified data when submitting manuscripts, if asked to do so.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2027, 25 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 25 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Oct 2025 → Nov 2025, primary completion May 2026 → Dec 2027 and completion May 2026 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2025
First posted
Oct 8, 2025
StartActual
Nov 15, 2025was Oct 2025
Primary completionEst.
Dec 15, 2027was May 2026
CompletionEst.
May 15, 2028was May 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
The University of Texas at El Paso, Rehabilitation Sciences Complex is now Recruiting
Oct 22, 2026
Start date
Oct 15, 2025→Nov 15, 2025 (actual)
Oct 22, 2026
Primary completion
May 15, 2026→Dec 15, 2027
Oct 22, 2026
Study completion
May 15, 2026→May 15, 2028
Oct 22, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionArm girth: how it is measured was reworded
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Recruiting
    The University of Texas at El Paso, Rehabilitation Sciences Complex is now Recruiting
    Start date Oct 15, 2025→Nov 15, 2025 (now actual)
    Primary completion May 15, 2026→Dec 15, 2027
    Study completion May 15, 2026→May 15, 2028
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionArm girth: how it is measured was reworded
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07211412
Lead sponsor
University of Texas, El Paso
Responsible party
Alvaro Gurovich (Professor and Chair, University of Texas, El Paso) — Principal investigator
First posted
Oct 8, 2025
Start date
Nov 15, 2025
Primary completion
Dec 15, 2027 (estimated)
Completion
May 15, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Alvaro N Gurovich, PT, PhD
Contact
agurovich@utep.edu
915-747-7248

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion